Target RWE, a Durham, NC-based real-world evidence (RWE) solutions company for the pharmaceutical and biotech industries, acquired NoviSci, Inc., a Durham-based software analytics and services company whose innovative technologies enable the visualization and analysis of health data using modern epidemiological methods and sound scientific principles.
Related to this acquisition, Amgen Inc., a strategic investor in and collaborator with NoviSci, has also made a strategic investment in the combined company to accelerate growth, joining existing Target RWE investors Norwest Venture Partners and 22C Capital.
The amount of the deal was not disclosed. The acquisition broadens Target RWE’s data analytics capabilities and will enable the company to meet the demand for high quality evidence from real-world data.
Led by Aaron McKethan, Co-Founder and CEO, and M. Alan Brookhart Ph.D., Co-Founder and Chief Scientist of NoviSci and Professor of Population Health Sciences at Duke University, NoviSci applies epidemiologic methods and causal inference techniques from the fields of epidemiology and statistics to complex real-world data to support its partners in research and industry. The company has built a novel repository of rigorously developed interactive real-world studies that can be adapted to new datasets and populations. All study results are rendered in NoviSci’s secure web-based environment, featuring interactive content and compelling data visualizations that can be updated with accumulating data. Tools also support all critical aspects of scientific knowledge production, peer review, and sharing.
Led by Neal Bibeau, Chief Executive Officer, and Michael W. Fried, MD, FAASLD, Chief Medical Officer and Co-founder, Target RWE is an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes as well as to improve patient health guidelines and quality of care. Target RWE designs custom data sets, analyses, and evidence to address the complexities of healthcare evidence questions and quality initiatives. Target RWE has developed a turnkey health evidence solution which rapidly aggregates real-world data (RWD) from a large network of participating sites (academic and community) across the United States, Europe, and other non-U.S. locations. Its data sets are aggregated from various data sources including registries, electronic medical records, patient outcomes measures, biospecimen analyses, and claims databases.